Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.31 |
| ▸ | PRKCG | P05129 | 2/20 | 0.31 |
| ▸ | PRKCB | P05771 | 2/20 | 0.31 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | PRKACA | P17612 | 2/20 | 0.31 |
| ▸ | PRKACG | P22612 | 2/20 | 0.31 |
| ▸ | PRKACB | P22694 | 2/20 | 0.31 |
| ▸ | PRKCH | P24723 | 2/20 | 0.31 |
| ▸ | PRKCI | P41743 | 2/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12339302 | 0.83 | DPP4 (0.31) | DPP4KCNH2 | |
| SCHEMBL16109047 | 0.83 | DPP4 (0.31) | DPP4KCNH2 | |
| SCHEMBL1118894 | 0.83 | DPP4 (0.31) | DPP4KCNH2 | |
| Hydrochloric Acid SCHEMBL2848909 | 0.81 | L3MBTL1 (0.33) | DPP4PRKD3PRKCGPRKCBPRKCA | |
| Hydrochloric Acid SCHEMBL3857650 | 0.81 | L3MBTL1 (0.33) | DPP4PRKD3PRKCGPRKCBPRKCA | |
| Hydrochloric Acid SCHEMBL2848912 | 0.81 | L3MBTL1 (0.33) | DPP4PRKD3PRKCGPRKCBPRKCA | |
| Hydrochloric Acid SCHEMBL2852782 | 0.81 | L3MBTL1 (0.33) | DPP4PRKD3PRKCGPRKCBPRKCA | |
| Hydrochloric Acid SCHEMBL2852784 | 0.81 | L3MBTL1 (0.33) | DPP4PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL27841744 | 0.80 | DPP4 (0.39) | HTR2CDPP4PLD1 | |
| SCHEMBL27841751 | 0.80 | DPP4 (0.39) | HTR2CDPP4PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | claimed |
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | claimed |
| JP-4674236-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | claimed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | claimed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| JP-2008510765-A | — | — | 2008-04-10 | — | — | JP | claimed |
| EP-1807429-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM, LLC (BM) | 2007-07-18 | — | — | EP | claimed |
| EP-1784399-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006047516-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2006-05-04 | — | — | WO | claimed |
| WO-2006021457-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-5658914-A | ANTIESTROGENS, ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658951-A | ANTIESTROGENS, ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES (US) | 1997-08-19 | — | — | US | disclosed |
| US-5422367-A | A hormon inhibitors and for inhibiting the development of an estrogen-dependent tumor | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-06-06 | — | — | US | disclosed |
| US-5324736-A | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5098903-A | Halocyclopropanes | BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293708-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | HTR2A 2876/4885HTR2C 2779/4885HTR2B 2132/4885 |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | HTR2A 361/4885HTR2C 189/4885HTR2B 454/4885 |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | HTR2A 361/4885HTR2C 189/4885HTR2B 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.